Johnson & Johnson
Since Abbott Labs
But you don't expect the health-care giant to lie down and die, do you? The company hasn't survived for over a century by giving up when competition got tough.
Johnson & Johnson is developing a next-generation drug-eluting stent called Nevo, and, so far, the data looks good. In a head-to-head test against Boston Scientific's
Nevo will also need to prove its worth against the new kid on the block, Abbott's Xience V, which is becoming the standard of care. Johnson & Johnson recently started a new trial to compare the stents, but data won't be available for a while.
The way the two areas have set up approval processes, Europe requires far less data for marketing approval than the U.S. Therefore, investors will likely get a European preview of how easy it will be for Johnson & Johnson to make a U.S. comeback in a few years.
Further Foolishness to help your portfolio make a comeback:
Johnson & Johnson is an Income Investor recommendation. To see how dividend-paying stocks can offer both secure income and the opportunity for growth, take a free look at this newsletter with a 30-day free trial.